Skip to Main Content

Rise and shine, everyone, another busy day is on the way. In fact, the middle of the week is already here. You made it this far, so why not continue, yes? Perhaps a cup or two of stimulation is in order. We have fired up the coffee kettle to brew some French vanilla. Feel free to join us as you attack the laundry list of meetings and deadlines that await. Meanwhile, we have once again assembled a list of tidbits for you to peruse and help you on your way. Hope you have a smashing day and, as always, do drop us a line when you hear something interesting. …

On the afternoon of Sept. 8, AstraZeneca (AZN) had a conference call with the Food and Drug Administration to ask what had to be done to win the agency’s blessing for the Covid-19 vaccine it was developing with the University of Oxford, The New York Times writes. But AstraZeneca neglected to mention a key development: Two days earlier, the company quietly halted trials around the world, including a late-stage study in the U.S. It acted after a participant in the U.K. fell ill. A few hours later, the story broke about the halted trials, which is how FDA officials heard the news.

Data from four studies show the Covid-19 vaccine being developed by AstraZeneca and Oxford appears to have moderate efficacy in preventing symptomatic illness, and may significantly reduce hospitalization from the disease, STAT notes. The highly anticipated publication of the data also point to some signals that deserve further exploration — the possibility of protection after a single dose and the suggestion that at least one dosing regimen may have led to a decrease in the number of asymptomatic infections.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!